Relay Therapeutics Q2 net loss $0.69/sh; cash $688M; new preclinical programs unveiled

Relay Therapeutics, Inc.

2024-Q2 EPS reported -$1.32 revenue$10,007,000

Q2 net loss $92.2M ($0.69/share) vs $98.5M ($0.81) in Q2 2023.
Cash, equivalents & investments $688.4M; expected to fund operations into H2 2026.
Announced 3 new preclinical programs: vascular malformations (PI3Kα), Fabry disease (non-inhibitory chaperone), NRAS-selective inhibitor.
Initiated Pfizer collaboration for RLY-2608 + fulvestrant + atirmociclib triplet; clinical start by end of 2024.
RLY-2608+fulvestrant doublet data update in Q4 2024 with ~100 patients safety database and ~60 at 600mg BID.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.